Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease
- Autores
- Silber, Ariel Mariano; Coli, Walter; Ulrich, Henning; Manso Alves, Maria; Pereira, Claudio Alejandro
- Año de publicación
- 2005
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Chagas' disease is a zoonosis caused by the parasite Trypanosoma cruzi, a haematic protozoan, transmitted by insects from the Reduviidae family. This constitutes a relevant health and socio-economic problem in the Americas, with 11 - 18 million people infected, and approximately 100 million people at risk. The therapeutic possibilities rely into two drugs, nifurtimox® and benznidazole®, that were discovered more than thirty years ago, and are mainly successful during the acute phase of the disease. In the majority of the cases the disease is diagnosed in the chronic phase, when the therapy is inefficient and the probability of cure is low. In addition, these drugs are highly toxic, with systemic side effects on patients. Trypanosoma cruzi has a metabolism largely based on the consumption of amino acids, mainly proline, aspartate and glutamate, which constitute the main carbon and energy sources in the insect stage of the parasite life cycle. These amino acids also participate in the differentiation process of the replicative non-infective form (epimastigote) to the non-replicative infective form (trypomastigote). In particular, the participation of proline in the intracellular differentiation cycle, which occurs in the mammalian host, was recently demonstrated. In addition, an arginine kinase has been described in T. cruzi and T. brucei, which converts free arginine to phosphoarginine, a phosphagen with a role as an energy reservoir. Arginine kinase seems to be an essential component of energy management during stress conditions. Taken together, these data indicate that amino acid metabolism may provide multiple as yet unexplored targets for therapeutic drugs.
Fil: Silber, Ariel Mariano. Universidade de Sao Paulo; Brasil
Fil: Coli, Walter. Universidade de Sao Paulo; Brasil
Fil: Ulrich, Henning. Universidade de Sao Paulo; Brasil
Fil: Manso Alves, Maria. Universidade de Sao Paulo; Brasil
Fil: Pereira, Claudio Alejandro. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
AMINO ACID TRANSPORTERS
APTAMERS
ARGININE METABOLISM
CHAGAS' DISEASE
CHEMOTHERAPY
PROLINE METABOLISM
TRYPANOSOMA CRUZI - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/194228
Ver los metadatos del registro completo
id |
CONICETDig_41e8c37dbf0e07558a4f4d1b6b111a66 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/194228 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' diseaseSilber, Ariel MarianoColi, WalterUlrich, HenningManso Alves, MariaPereira, Claudio AlejandroAMINO ACID TRANSPORTERSAPTAMERSARGININE METABOLISMCHAGAS' DISEASECHEMOTHERAPYPROLINE METABOLISMTRYPANOSOMA CRUZIhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Chagas' disease is a zoonosis caused by the parasite Trypanosoma cruzi, a haematic protozoan, transmitted by insects from the Reduviidae family. This constitutes a relevant health and socio-economic problem in the Americas, with 11 - 18 million people infected, and approximately 100 million people at risk. The therapeutic possibilities rely into two drugs, nifurtimox® and benznidazole®, that were discovered more than thirty years ago, and are mainly successful during the acute phase of the disease. In the majority of the cases the disease is diagnosed in the chronic phase, when the therapy is inefficient and the probability of cure is low. In addition, these drugs are highly toxic, with systemic side effects on patients. Trypanosoma cruzi has a metabolism largely based on the consumption of amino acids, mainly proline, aspartate and glutamate, which constitute the main carbon and energy sources in the insect stage of the parasite life cycle. These amino acids also participate in the differentiation process of the replicative non-infective form (epimastigote) to the non-replicative infective form (trypomastigote). In particular, the participation of proline in the intracellular differentiation cycle, which occurs in the mammalian host, was recently demonstrated. In addition, an arginine kinase has been described in T. cruzi and T. brucei, which converts free arginine to phosphoarginine, a phosphagen with a role as an energy reservoir. Arginine kinase seems to be an essential component of energy management during stress conditions. Taken together, these data indicate that amino acid metabolism may provide multiple as yet unexplored targets for therapeutic drugs.Fil: Silber, Ariel Mariano. Universidade de Sao Paulo; BrasilFil: Coli, Walter. Universidade de Sao Paulo; BrasilFil: Ulrich, Henning. Universidade de Sao Paulo; BrasilFil: Manso Alves, Maria. Universidade de Sao Paulo; BrasilFil: Pereira, Claudio Alejandro. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaBentham Science Publishers Ltd.2005-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/194228Silber, Ariel Mariano; Coli, Walter; Ulrich, Henning; Manso Alves, Maria; Pereira, Claudio Alejandro; Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease; Bentham Science Publishers Ltd.; Current Drug Targets - Infectious Disorders; 5; 1; 12-2005; 53-641568-0053CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.2174/1568005053174636info:eu-repo/semantics/altIdentifier/url/https://www.eurekaselect.com/article/35385info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:35:35Zoai:ri.conicet.gov.ar:11336/194228instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:35:35.69CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease |
title |
Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease |
spellingShingle |
Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease Silber, Ariel Mariano AMINO ACID TRANSPORTERS APTAMERS ARGININE METABOLISM CHAGAS' DISEASE CHEMOTHERAPY PROLINE METABOLISM TRYPANOSOMA CRUZI |
title_short |
Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease |
title_full |
Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease |
title_fullStr |
Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease |
title_full_unstemmed |
Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease |
title_sort |
Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease |
dc.creator.none.fl_str_mv |
Silber, Ariel Mariano Coli, Walter Ulrich, Henning Manso Alves, Maria Pereira, Claudio Alejandro |
author |
Silber, Ariel Mariano |
author_facet |
Silber, Ariel Mariano Coli, Walter Ulrich, Henning Manso Alves, Maria Pereira, Claudio Alejandro |
author_role |
author |
author2 |
Coli, Walter Ulrich, Henning Manso Alves, Maria Pereira, Claudio Alejandro |
author2_role |
author author author author |
dc.subject.none.fl_str_mv |
AMINO ACID TRANSPORTERS APTAMERS ARGININE METABOLISM CHAGAS' DISEASE CHEMOTHERAPY PROLINE METABOLISM TRYPANOSOMA CRUZI |
topic |
AMINO ACID TRANSPORTERS APTAMERS ARGININE METABOLISM CHAGAS' DISEASE CHEMOTHERAPY PROLINE METABOLISM TRYPANOSOMA CRUZI |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Chagas' disease is a zoonosis caused by the parasite Trypanosoma cruzi, a haematic protozoan, transmitted by insects from the Reduviidae family. This constitutes a relevant health and socio-economic problem in the Americas, with 11 - 18 million people infected, and approximately 100 million people at risk. The therapeutic possibilities rely into two drugs, nifurtimox® and benznidazole®, that were discovered more than thirty years ago, and are mainly successful during the acute phase of the disease. In the majority of the cases the disease is diagnosed in the chronic phase, when the therapy is inefficient and the probability of cure is low. In addition, these drugs are highly toxic, with systemic side effects on patients. Trypanosoma cruzi has a metabolism largely based on the consumption of amino acids, mainly proline, aspartate and glutamate, which constitute the main carbon and energy sources in the insect stage of the parasite life cycle. These amino acids also participate in the differentiation process of the replicative non-infective form (epimastigote) to the non-replicative infective form (trypomastigote). In particular, the participation of proline in the intracellular differentiation cycle, which occurs in the mammalian host, was recently demonstrated. In addition, an arginine kinase has been described in T. cruzi and T. brucei, which converts free arginine to phosphoarginine, a phosphagen with a role as an energy reservoir. Arginine kinase seems to be an essential component of energy management during stress conditions. Taken together, these data indicate that amino acid metabolism may provide multiple as yet unexplored targets for therapeutic drugs. Fil: Silber, Ariel Mariano. Universidade de Sao Paulo; Brasil Fil: Coli, Walter. Universidade de Sao Paulo; Brasil Fil: Ulrich, Henning. Universidade de Sao Paulo; Brasil Fil: Manso Alves, Maria. Universidade de Sao Paulo; Brasil Fil: Pereira, Claudio Alejandro. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
description |
Chagas' disease is a zoonosis caused by the parasite Trypanosoma cruzi, a haematic protozoan, transmitted by insects from the Reduviidae family. This constitutes a relevant health and socio-economic problem in the Americas, with 11 - 18 million people infected, and approximately 100 million people at risk. The therapeutic possibilities rely into two drugs, nifurtimox® and benznidazole®, that were discovered more than thirty years ago, and are mainly successful during the acute phase of the disease. In the majority of the cases the disease is diagnosed in the chronic phase, when the therapy is inefficient and the probability of cure is low. In addition, these drugs are highly toxic, with systemic side effects on patients. Trypanosoma cruzi has a metabolism largely based on the consumption of amino acids, mainly proline, aspartate and glutamate, which constitute the main carbon and energy sources in the insect stage of the parasite life cycle. These amino acids also participate in the differentiation process of the replicative non-infective form (epimastigote) to the non-replicative infective form (trypomastigote). In particular, the participation of proline in the intracellular differentiation cycle, which occurs in the mammalian host, was recently demonstrated. In addition, an arginine kinase has been described in T. cruzi and T. brucei, which converts free arginine to phosphoarginine, a phosphagen with a role as an energy reservoir. Arginine kinase seems to be an essential component of energy management during stress conditions. Taken together, these data indicate that amino acid metabolism may provide multiple as yet unexplored targets for therapeutic drugs. |
publishDate |
2005 |
dc.date.none.fl_str_mv |
2005-12 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/194228 Silber, Ariel Mariano; Coli, Walter; Ulrich, Henning; Manso Alves, Maria; Pereira, Claudio Alejandro; Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease; Bentham Science Publishers Ltd.; Current Drug Targets - Infectious Disorders; 5; 1; 12-2005; 53-64 1568-0053 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/194228 |
identifier_str_mv |
Silber, Ariel Mariano; Coli, Walter; Ulrich, Henning; Manso Alves, Maria; Pereira, Claudio Alejandro; Amino acid metabolic routes in Trypanosoma cruzi: Possible therapeutic targets against Chagas' disease; Bentham Science Publishers Ltd.; Current Drug Targets - Infectious Disorders; 5; 1; 12-2005; 53-64 1568-0053 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.2174/1568005053174636 info:eu-repo/semantics/altIdentifier/url/https://www.eurekaselect.com/article/35385 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Bentham Science Publishers Ltd. |
publisher.none.fl_str_mv |
Bentham Science Publishers Ltd. |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614374615941120 |
score |
13.070432 |